The KEYNOTE-024 trial indicated that pembrolizumab was associated with significantly longer progression-free survival (PFS) and overall survival (OS) than platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 expressed on at least 50% of tumor cells1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.